OA-235i is under clinical development by Oasis Pharmaceuticals and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase I drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OA-235i’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OA-235i overview

OA-235i is under development for the treatment of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis, metastatic hepatocellular carcinoma (HCC), atopic dermatitis and inflammatory bowel disease (IBD). It acts by targeting protease activated receptor 2 (PAR-2). It is a pepducin compound. It is being developed based on Pepducin technology. Pepducin compounds are lipidated peptides that target specific intracellular loops of G-protein-coupled receptors (GPCRs) and are allosteric modulators of GPCR activity. It is administered through topical and subcutaneous route.

It was also under development for kidney fibrosis and pain. It is administered through topical and subcutaneous route.

For a complete picture of OA-235i’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.